RNA治療臨床試驗市場－全球產業規模、佔有率、趨勢、機會及預測（按類型、階段、治療領域、地區及競爭格局分類，2021-2031年）

全球 RNA 治療臨床試驗市場預計將從 2025 年的 31.7 億美元成長到 2031 年的 42.8 億美元，複合年成長率為 5.13%。

這個領域涉及對各種基於RNA的治療方法（包括mRNA疫苗、反義寡核苷酸和RNA干擾療法）在治療遺傳性和獲得性疾病方面的安全性和有效性進行研究。成長要素的關鍵因素包括慢性病和罕見疾病發病率的上升，以及藥物遞送技術的顯著進步，例如脂質奈米顆粒，這些技術能夠提高藥物穩定性和細胞吸收率。美國基因與細胞治療學會（ASGCT）報告稱，2025年第二季已有38項新的RNA療法臨床試驗啟動，這就是該領域研發管線穩定成長的例證。

然而，市場擴張的一大障礙在於難以有效針對肝臟以外的其他組織。 RNA分子固有的不穩定性，加上製造安全、高純度遞送系統的複雜性，為研發人員帶來了巨大的技術和經濟挑戰。因此，解決這些穩定性和遞送問題是獲得監管部門核准和下一代RNA療法成功商業化的關鍵前提。

市場促進因素

推動全球RNA療法臨床試驗市場發展的關鍵因素是創業投資和政府資金的大量湧入，這使得生物技術公司能夠繼續進行資本密集的研發活動。鑑於生產和安全性測試的高昂成本，這種資金支持對於將早期候選藥物推進到後期臨床試驗至關重要。此外，資金的充足也促進了研發管線的多元化，使其不再局限於感染疾病，而是拓展至癌症治療和罕見遺傳疾病治療，有助於降低系統性風險。為了證明投資者的韌性，再生醫學聯盟於2024年10月宣布，包括RNA療法在內的更廣泛的細胞和基因治療領域在2024年上半年獲得了109億美元的投資。

同時，mRNA技術平台在疫情期間的成功，促使人們的關注點從預防性疫苗轉向治療性疫苗，為市場加速發展奠定了堅實的基礎。 mRNA已被證實能夠實現體內蛋白質生產，這降低了監管機構和投資者的風險，並促進了癌症免疫療法和蛋白質替代策略等新型應用的研究。這種技術的成熟正在帶來切實可見的監管成果，進一步加速臨床應用。例如，2024年5月，Moderna公司宣布，美國食品藥物管理局（FDA）核准了mRESVIA，一種用於預防60歲及以上成年人感染呼吸道融合細胞病毒（RSV）的疫苗。這是首個核准的非新冠病毒mRNA疫苗。此外，國際細胞與基因治療學會（ISCT）報告稱，2024年全年共有七種不同的細胞和基因治療產品獲得FDA核准，凸顯了支持該市場的監管勢頭。

市場挑戰

全球RNA療法臨床試驗市場的主要障礙在於，將治療藥物有效地遞送至肝臟以外的組織存在技術複雜性，以及RNA分子本身的不穩定性。雖然現有的遞送系統（例如脂質奈米顆粒）對肝臟靶向有效，但將其應用於其他器官則需要複雜的設計，這往往會導致穩定性降低和毒性增加。這項限制迫使藥物研發人員在複雜的生產流程上投入巨資，以確保遞送系統的高純度，從而顯著增加研發成本並延長研發週期。因此，與穩定性和遞送問題相關的臨床試驗失敗風險增加，導致投資環境趨於謹慎，使得許多有前景的候選藥物止步於臨床前階段，而未能進入人體試驗階段。

這項技術瓶頸顯然正在減緩市場擴張的步伐。根據美國基因與細胞治療學會（ASGCT）的數據顯示，2025年第三季度，基因治療、細胞治療和RNA治療等廣泛領域的臨床開發活動有所放緩，這些領域總合啟動了125項試驗。這一放緩表明，儘管人們對RNA療法表現出濃厚的興趣，但克服遞送和穩定性障礙方面持續存在的困難阻礙了研究成果快速轉化為臨床試驗，從而限制了市場的整體成長。

市場趨勢

個人化mRNA癌症疫苗試驗的加速推進，正從根本上改變市場格局，將傳訊RNA技術的應用從感染疾病預防轉向精準癌症治療。借助疫情期間快速發展的生產能力，研發人員正在開發針對患者特異性腫瘤新抗原的個人化免疫療法，以應對固體癌瘤的高復發率。同時，由於需要檢驗mRNA在複雜癌症病例中的治療潛力，早期安全性試驗正迅速推進至大規模療效試驗。為了支持這一積極成長，BioNTech在其2024年11月的財務報告中確認，其目標是在2024年底前開展超過10項有望進入臨床實驗註冊階段的癌症治療產品試驗，這標誌著後期研發工作將顯著增加。

同時，RNA編輯療法的臨床計畫拓展代表著該領域的一項重要進展，其發展方向已從基因靜默和替換轉向在轉錄層面上精確糾正基因突變。這種方法利用細胞內在機制，例如ADAR酶，在不永久改變基因組DNA的情況下暫時編輯RNA序列，與基於CRISPR的編輯方法相比，為治療慢性遺傳疾病提供了更安全的選擇。近年來，該方法已從理論潛力走向臨床檢驗，確立了一種新的治療類別。例如，2024年10月，Wave Life Sciences公司報告了首個在人體中進行的治療性RNA編輯研究－Ib/IIa期臨床試驗「RestorAATion-2」。接受WVE-006治療的患者體內野生型M-AAT蛋白的平均恢復率超過總AAT蛋白的60%。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球RNA療法臨床試驗市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 按方式（RNA干擾、反義療法、傳訊RNA、寡核苷酸、非反義、非RNAi）
  • 依研發階段（I期、II期、III期、IV期）
  • 依治療領域（罕見疾病、抗感染、抗癌、神經系統、胃腸道/代謝、肌肉骨骼、心血管/呼吸系統、感覺系統、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美RNA療法臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲RNA療法臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區RNA療法臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲RNA療法臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美RNA療法臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球RNA療法臨床試驗市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• IQVIA Inc.
• ICON Plc
• Laboratory Corporation of America Holdings
• Charles River Laboratories International, Inc.
• PAREXEL International Corp.
• Syneos Health
• Medpace Holdings, Inc.
• Novotech Inc.
• PPD Inc.
• Veristat, LLC.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global RNA Therapy Clinical Trials Market is projected to expand from USD 3.17 Billion in 2025 to USD 4.28 Billion by 2031, registering a compound annual growth rate of 5.13%. This sector encompasses research studies aimed at assessing the safety and effectiveness of various RNA-based treatments, such as mRNA vaccines, antisense oligonucleotides, and RNA interference therapies for both genetic and acquired conditions. Key growth drivers include the rising incidence of chronic and rare diseases, as well as significant advancements in delivery technologies like lipid nanoparticles, which improve the stability and cellular absorption of these drugs. Illustrating this consistent pipeline growth, the American Society of Gene & Cell Therapy reported that 38 new RNA therapy clinical trials were launched in the second quarter of 2025.

However, a significant obstacle to broader market expansion is the difficulty of successfully targeting tissues outside the liver. The natural instability of RNA molecules, combined with the intricacies of manufacturing safe, high-purity delivery systems, presents considerable technical and financial challenges for developers. Consequently, resolving these stability and distribution issues is a vital precondition for securing regulatory approval and achieving the successful commercialization of next-generation RNA therapeutics.

Market Driver

A major force driving the Global RNA Therapy Clinical Trials Market is the significant influx of venture capital and government funding, which empowers biotechnology companies to maintain capital-intensive research and development efforts. This financial support is crucial for advancing early-stage candidates into later clinical phases, given the substantial costs involved in manufacturing and safety testing. Furthermore, access to capital facilitates pipeline diversification beyond infectious diseases into areas like oncology and rare genetic disorders, thereby lowering systemic risk. As evidence of investor resilience, the Alliance for Regenerative Medicine noted in October 2024 that the broader cell and gene therapy sector, which includes RNA therapeutics, secured $10.9 billion in investment during the first half of the year.

In parallel, the proven success of mRNA technology platforms during the pandemic has created a strong basis for market acceleration, transitioning focus from prophylactic vaccines to therapeutic treatments. The demonstrated ability of mRNA to generate protein production in vivo has reduced risks for regulators and investors, prompting the investigation of novel uses such as cancer immunotherapies and protein replacement strategies. This technical maturity is resulting in tangible regulatory achievements that further boost clinical activity. For instance, Moderna reported in May 2024 that the U.S. FDA approved mRESVIA for protecting adults aged 60 and older against respiratory syncytial virus, the first non-COVID mRNA vaccine approval, while the International Society for Cell & Gene Therapy noted that seven distinct cell and gene therapy products received FDA approval throughout 2024, highlighting the regulatory momentum supporting this market.

Market Challenge

The principal hindrance to the Global RNA Therapy Clinical Trials Market is the technical complexity involved in delivering therapies effectively to tissues other than the liver, alongside the inherent instability of RNA molecules. Although existing delivery vehicles such as lipid nanoparticles work well for hepatic targets, adapting them for other organs necessitates complex engineering that often degrades stability or increases toxicity. This constraint compels pharmaceutical developers to invest heavily in intricate manufacturing processes to guarantee high-purity delivery systems, which significantly raises development costs and lengthens timelines. As a result, the elevated risk of clinical failure linked to these stability and distribution issues creates a hesitant investment climate, causing many potential candidates to stall in preclinical stages rather than progressing to human trials.

This technical bottleneck creates a measurable drag on the market's rate of expansion. According to the American Society of Gene & Cell Therapy, clinical development activity across the broader gene, cell, and RNA therapy landscape slowed in the third quarter of 2025, with a total of 125 trials initiated across these sectors. This deceleration suggests that despite significant interest in RNA therapeutics, the persistent difficulty in overcoming delivery and stability barriers is impeding the rapid translation of research into active clinical studies, thereby moderating the overall growth trajectory of the market.

Market Trends

The acceleration of personalized mRNA cancer vaccine trials is fundamentally transforming the market by shifting the application of messenger RNA technology from preventing infectious diseases to precision oncology. Developers are utilizing rapid manufacturing capabilities honed during the pandemic to create patient-specific immunotherapies targeting unique tumor neoantigens, aiming to address high recurrence rates in solid tumors. This trend involves a quick progression from early-phase safety studies to large-scale efficacy trials, driven by the necessity to validate the therapeutic potential of mRNA in complex cancer cases. Highlighting this aggressive growth, BioNTech confirmed in its November 2024 financial update an objective to have ten or more potentially registrational trials in its oncology pipeline by the end of 2024, indicating a substantial increase in late-stage development.

Simultaneously, the expansion of RNA-editing therapeutic clinical programs marks a significant evolution in the sector, advancing from gene silencing or replacement to the precise correction of genetic mutations at the transcript level. This method employs endogenous cellular machinery, such as ADAR enzymes, to transiently edit RNA sequences without permanently modifying genomic DNA, providing a safer alternative to CRISPR-based editing for chronic genetic disorders. This approach has recently moved from theoretical potential to clinical validation, confirming a new class of therapeutics. For example, Wave Life Sciences reported in October 2024 that its Phase 1b/2a RestorAATion-2 study achieved the first-ever therapeutic RNA editing in humans, with patients treated with WVE-006 showing a mean wild-type M-AAT protein restoration of over 60% of total AAT.

Key Market Players

• IQVIA Inc.
• ICON Plc
• Laboratory Corporation of America Holdings
• Charles River Laboratories International, Inc.
• PAREXEL International Corp.
• Syneos Health
• Medpace Holdings, Inc.
• Novotech Inc.
• PPD Inc.
• Veristat, LLC.

Report Scope

In this report, the Global RNA Therapy Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

RNA Therapy Clinical Trials Market, By Modality

• RNA interference
• Antisense therapy
• Messenger RNA
• Oligonucleotide
• non-antisense
• non-RNAi

RNA Therapy Clinical Trials Market, By Phase

• Phase I
• Phase II
• Phase III
• Phase IV

RNA Therapy Clinical Trials Market, By Therapeutic Areas

• Rare Diseases
• Anti-infective
• Anticancer
• Neurological
• Alimentary/Metabolic
• Musculoskeletal
• Cardiovascular Respiratory
• Sensory
• Others

RNA Therapy Clinical Trials Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global RNA Therapy Clinical Trials Market.

Available Customizations:

Global RNA Therapy Clinical Trials Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global RNA Therapy Clinical Trials Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Modality (RNA interference, Antisense therapy, Messenger RNA, Oligonucleotide, non-antisense, non-RNAi)
  • 5.2.2. By Phase (Phase I, Phase II, Phase III, Phase IV)
  • 5.2.3. By Therapeutic Areas (Rare Diseases, Anti-infective, Anticancer, Neurological, Alimentary/Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America RNA Therapy Clinical Trials Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Modality
  • 6.2.2. By Phase
  • 6.2.3. By Therapeutic Areas
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States RNA Therapy Clinical Trials Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Modality
      • 6.3.1.2.2. By Phase
      • 6.3.1.2.3. By Therapeutic Areas
  • 6.3.2. Canada RNA Therapy Clinical Trials Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Modality
      • 6.3.2.2.2. By Phase
      • 6.3.2.2.3. By Therapeutic Areas
  • 6.3.3. Mexico RNA Therapy Clinical Trials Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Modality
      • 6.3.3.2.2. By Phase
      • 6.3.3.2.3. By Therapeutic Areas

7. Europe RNA Therapy Clinical Trials Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Modality
  • 7.2.2. By Phase
  • 7.2.3. By Therapeutic Areas
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany RNA Therapy Clinical Trials Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Modality
      • 7.3.1.2.2. By Phase
      • 7.3.1.2.3. By Therapeutic Areas
  • 7.3.2. France RNA Therapy Clinical Trials Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Modality
      • 7.3.2.2.2. By Phase
      • 7.3.2.2.3. By Therapeutic Areas
  • 7.3.3. United Kingdom RNA Therapy Clinical Trials Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Modality
      • 7.3.3.2.2. By Phase
      • 7.3.3.2.3. By Therapeutic Areas
  • 7.3.4. Italy RNA Therapy Clinical Trials Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Modality
      • 7.3.4.2.2. By Phase
      • 7.3.4.2.3. By Therapeutic Areas
  • 7.3.5. Spain RNA Therapy Clinical Trials Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Modality
      • 7.3.5.2.2. By Phase
      • 7.3.5.2.3. By Therapeutic Areas

8. Asia Pacific RNA Therapy Clinical Trials Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Modality
  • 8.2.2. By Phase
  • 8.2.3. By Therapeutic Areas
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China RNA Therapy Clinical Trials Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Modality
      • 8.3.1.2.2. By Phase
      • 8.3.1.2.3. By Therapeutic Areas
  • 8.3.2. India RNA Therapy Clinical Trials Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Modality
      • 8.3.2.2.2. By Phase
      • 8.3.2.2.3. By Therapeutic Areas
  • 8.3.3. Japan RNA Therapy Clinical Trials Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Modality
      • 8.3.3.2.2. By Phase
      • 8.3.3.2.3. By Therapeutic Areas
  • 8.3.4. South Korea RNA Therapy Clinical Trials Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Modality
      • 8.3.4.2.2. By Phase
      • 8.3.4.2.3. By Therapeutic Areas
  • 8.3.5. Australia RNA Therapy Clinical Trials Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Modality
      • 8.3.5.2.2. By Phase
      • 8.3.5.2.3. By Therapeutic Areas

9. Middle East & Africa RNA Therapy Clinical Trials Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Modality
  • 9.2.2. By Phase
  • 9.2.3. By Therapeutic Areas
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia RNA Therapy Clinical Trials Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Modality
      • 9.3.1.2.2. By Phase
      • 9.3.1.2.3. By Therapeutic Areas
  • 9.3.2. UAE RNA Therapy Clinical Trials Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Modality
      • 9.3.2.2.2. By Phase
      • 9.3.2.2.3. By Therapeutic Areas
  • 9.3.3. South Africa RNA Therapy Clinical Trials Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Modality
      • 9.3.3.2.2. By Phase
      • 9.3.3.2.3. By Therapeutic Areas

10. South America RNA Therapy Clinical Trials Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Modality
  • 10.2.2. By Phase
  • 10.2.3. By Therapeutic Areas
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil RNA Therapy Clinical Trials Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Modality
      • 10.3.1.2.2. By Phase
      • 10.3.1.2.3. By Therapeutic Areas
  • 10.3.2. Colombia RNA Therapy Clinical Trials Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Modality
      • 10.3.2.2.2. By Phase
      • 10.3.2.2.3. By Therapeutic Areas
  • 10.3.3. Argentina RNA Therapy Clinical Trials Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Modality
      • 10.3.3.2.2. By Phase
      • 10.3.3.2.3. By Therapeutic Areas

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global RNA Therapy Clinical Trials Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. IQVIA Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. ICON Plc
• 15.3. Laboratory Corporation of America Holdings
• 15.4. Charles River Laboratories International, Inc.
• 15.5. PAREXEL International Corp.
• 15.6. Syneos Health
• 15.7. Medpace Holdings, Inc.
• 15.8. Novotech Inc.
• 15.9. PPD Inc.
• 15.10. Veristat, LLC.

16. Strategic Recommendations

17. About Us & Disclaimer